NCT06904300View on ClinicalTrials.gov

Ivonescimab (AK112) Plus Paclitaxel as Second-line Therapy in Patients With Advanced G/GEJ Cancer

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

110

Participants

Timeline

Start Date

August 15, 2025

Primary Completion Date

April 30, 2028

Study Completion Date

December 31, 2028

Conditions
Gastric (Cardia, Body) Cancer
Interventions
DRUG

AK112 + paclitaxel

AK112 (20 mg/kg IV, D1/D15) + paclitaxel (80 mg/m² IV, D1/D8/D15), Q4W

DRUG

Paclitaxel ± ramucirumab

Paclitaxel (80 mg/m² IV, D1/D8/D15) ± ramucirumab (8 mg/kg IV, D1/D15), Q4W

All Listed Sponsors
lead

Sun Yat-sen University

OTHER